联合靶向治疗和免疫治疗结直肠癌的进展。

Advancements in combining targeted therapy and immunotherapy for colorectal cancer.

机构信息

Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Trends Cancer. 2024 Jul;10(7):598-609. doi: 10.1016/j.trecan.2024.05.001. Epub 2024 May 31.

Abstract

Colorectal cancer (CRC) is a prevalent gastrointestinal cancer posing significant clinical challenges. CRC management traditionally involves surgery, often coupled with chemotherapy. However, unresectable or metastatic CRC (mCRC) presents a complex challenge necessitating innovative treatment strategies. Targeted therapies have emerged as the cornerstone of treatment in such cases, with interventions tailored to specific molecular attributes. Concurrently, immunotherapies have revolutionized cancer treatment by harnessing the immune system to combat malignant cells. This review explores the evolving landscape of CRC treatment, focusing on the synergy between immunotherapies and targeted therapies, thereby offering new avenues for enhancing the effectiveness of therapy for CRC.

摘要

结直肠癌(CRC)是一种常见的胃肠道癌症,给临床带来了巨大挑战。CRC 的传统治疗方法包括手术,通常结合化疗。然而,不可切除或转移性 CRC(mCRC)则是一个复杂的难题,需要创新的治疗策略。在这种情况下,靶向治疗已成为治疗的基石,干预措施针对特定的分子特征进行定制。同时,免疫疗法通过利用免疫系统来对抗恶性细胞,彻底改变了癌症治疗。本综述探讨了结直肠癌治疗的不断发展的格局,重点关注免疫疗法和靶向治疗之间的协同作用,从而为提高 CRC 治疗效果提供了新途径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索